AbCellera Biologics Inc. Construction in Progress, Gross
AbCellera Biologics Inc. (ABCL) had Construction in Progress, Gross of $13.00 million as of 2024-06-30, per its 10-Q filed 2024-08-06.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent › Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization › Property, Plant, and Equipment, before Accumulated Depreciation, Depletion, and Amortization
us-gaap:ConstructionInProgressGross · last filed 2024-08-06
- 2024-06-30: Construction in Progress, Gross $13.00M.
- 2024-03-31: Construction in Progress, Gross $15.20M.
- 2023-12-31: Construction in Progress, Gross $13.70M.
- 2023-09-30: Construction in Progress, Gross $13.20M.
| Period end | Construction in Progress, Gross |
|---|---|
| 2024-06-30 | $13.00M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $15.20M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $13.70M 10-Q · filed 2024-08-06 |
| 2023-09-30 | $13.20M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $10.50M 10-Q · filed 2023-08-03 |
| 2022-12-31 | $0.00 10-K · filed 2024-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |